Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ovid Therapeutics Inc (OVID)

Ovid Therapeutics Inc (OVID)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Ovid Therapeutics Inc 441 Ninth Avenue 14th Floor New York NY 10001 USA

www.ovidrx.com Employees: 23 P: 646-661-7661 F: 646-661-4027

Sector:

Medical

Description:

Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company's product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid Therapeutics Inc. is based in New York, United States.

Key Statistics

Overview:

Market Capitalization, $K 116,788
Enterprise Value, $K 90,488
Shares Outstanding, K 71,212
Float, K 61,883
% Float 86.90%
Short Interest, K 4,384
Short Float 6.16%
Days to Cover 2.62
Short Volume Ratio 0.31
% of Insider Shareholders 13.10%
% of Institutional Shareholders 72.24%

Financials:

Annual Sales, $ 570 K
Annual Net Income, $ -26,430 K
Last Quarter Sales, $ 130 K
Last Quarter Net Income, $ -12,160 K
EBIT, $ -40,870 K
EBITDA, $ -40,260 K

Growth:

1-Year Return 134.71%
3-Year Return -35.18%
5-Year Return -41.64%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 75.97%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.17 on 11/12/25
Next Earnings Date 03/10/26
Earnings Per Share ttm -0.50
EPS Growth vs. Prev Qtr -183.33%
EPS Growth vs. Prev Year 15.00%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 12/02/20

OVID Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -63.79%
Return-on-Assets % -46.15%
Profit Margin % -4,636.84%
Debt/Equity 0.00
Price/Sales 17.74
Price/Cash Flow N/A
Price/Book 2.50
Book Value/Share 0.63
Interest Coverage -0.03
60-Month Beta 0.22
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar